CYAN Cyanotech Dashboard

Cyanotech Corp. engages in the development and commercialization of natural products derived from microalgae. Its products include BioAstin natural astaxanthin, a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health; and Spirulina Pacifica, a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Company profile

Ticker

CYAN

Exchange

NASDAQ

Website

www.cyanotech.com

CEO

Gerald R. Cysewski

Incorporated

Nevada

Location

Hawaii

Fiscal year end

Mar 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Medicinal Chemicals & Botanical Products

Usana Health Sciences • 4Front Ventures • Sundial Growers • Mannatech • Tilray • Happiness Biotech • Foamix Pharmaceuticals • Hanjiao • Natural Alternatives International • Heyu Biological Technology ...

SEC CIK

0000768408

Corporate docs

Articles of Incorporation & Bylaws

IRS number

911206026

CYAN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Wrapping Up March With With A Steady Green Streak

5 Apr 21

It shouldn’t be so surprising now after months of huge moves in the market, but March was another stellar month for my day trading accounts.

66 Biggest Movers From Yesterday

31 Mar 21

Gainers

41 Stocks Moving In Tuesday's Mid-Day Session

30 Mar 21

Gainers VirTra, Inc. (NASDAQ: VTSI) shares jumped 53.6% to $7.34 after the company reported better-than-expected Q4 results.

33 Stocks Moving in Tuesday's Pre-Market Session

30 Mar 21

50 Biggest Movers From Yesterday

30 Mar 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in China Pharma, Naked Brand, Rocket Companies, AMC Entertainment, or Cyanotech Corp?

29 Mar 21

NEW YORK, March 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CPHI, NAKD, RKT, AMC, and CYAN.

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 Feb 21

22 Apr 21

31 Mar 22

Financial summary

Financial statements Chart CYAN financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 20	Mar 19	Mar 18	Mar 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Cyanotech earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.32M	3.32M	3.32M	3.32M	3.32M	3.32M
Cash burn (monthly)	310.33K	(positive/no burn)	(positive/no burn)	(positive/no burn)	74K	(positive/no burn)
Cash used (since last report)	1.16M	n/a	n/a	n/a	276.85K	n/a
Cash remaining	2.16M	n/a	n/a	n/a	3.05M	n/a
Runway (months of cash)	7.0	n/a	n/a	n/a	41.2	n/a

Beta Read what these cash burn values mean

Recent insider trades

CYAN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Apr 21	Cysewski Gerald R	Common Stock	Payment of exercise	Dispose F	No	No	3.35	13	43.55	137,087
6 Apr 21	Cysewski Gerald R	Common Stock	Option exercise	Aquire M	No	No	0	33	0	137,100
6 Apr 21	Cysewski Gerald R	RSU Common Stock	Option exercise	Dispose M	No	No	0	33	0	2,802
6 Apr 21	Jensen Glenn	Common Stock	Payment of exercise	Dispose F	No	No	3.35	13	43.55	17,916
6 Apr 21	Jensen Glenn	Common Stock	Option exercise	Aquire M	No	No	0	33	0	17,929
6 Apr 21	Jensen Glenn	RSU Common Stock	Option exercise	Dispose M	No	No	0	33	0	2,262
6 Apr 21	Johansen Jennifer M.	Common Stock	Payment of exercise	Dispose F	No	No	3.35	13	43.55	1,878
6 Apr 21	Johansen Jennifer M.	Common Stock	Option exercise	Aquire M	No	No	0	33	0	1,891
6 Apr 21	Johansen Jennifer M.	RSU Common Stock	Option exercise	Dispose M	No	No	0	33	0	1,996
6 Apr 21	Nordin Amy Beth	Common Stock	Option exercise	Aquire M	No	No	0	33	0	727

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

CYAN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

11.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	9	10	-10.0%
Opened positions	0	0
Closed positions	1	0	NEW
Increased positions	2	4	-50.0%
Reduced positions	2	2	–

13F shares	Current	Prev Q	Change
Total value	2.09M	1.69M	+23.7%
Total shares	687.39K	689.98K	-0.4%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
WFC Wells Fargo & Co.	375.17K	$1.14M	0.0%
Renaissance Technologies	182.13K	$554K	+9.3%
Coastline Trust	82.4K	$250K	0.0%
MS Morgan Stanley	14.84K	$45K	0.0%
Heritage Investors Management	13.79K	$42K	0.0%
BLK Blackrock	11.57K	$35K	0.0%
Tower Research Capital	2.79K	$8K	+890.8%
BAC Bank Of America	2.5K	$8K	-34.2%
NTRS Northern Trust	2.2K	$7K	-1.8%
Proequities	0	$0

Largest transactions	Shares	Bought/sold	Change
California Public Employees Retirement System	0	-19.3K	EXIT
Renaissance Technologies	182.13K	+15.53K	+9.3%
Tower Research Capital	2.79K	+2.51K	+890.8%
BAC Bank Of America	2.5K	-1.3K	-34.2%
NTRS Northern Trust	2.2K	-41	-1.8%
WFC Wells Fargo & Co.	375.17K	0	0.0%
Proequities	0	0
MS Morgan Stanley	14.84K	0	0.0%
Heritage Investors Management	13.79K	0	0.0%
Coastline Trust	82.4K	0	0.0%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Cardax

Management Discussion

Net Sales The net sales increased $1.7 million, or 5.6%, in the year ended March 31, 2020 compared with fiscal year 2019. This increase was primarily driven by a $2.2 million, or 68.0%, increase in both astaxanthin and spirulina bulk sales and an increase in contract extraction sales of $0.3 million, offset by $0.8 million, or 3.2%, decrease in packaged sales when compared with fiscal year 2019. The bulk sales increase was primarily the result of lack of product available for our bulk customers in the prior year. The decrease in packaged sales for astaxanthin was the result of non-recurring replenishment orders in fiscal year 2019, that were the result of depleted inventory related to the re-inoculation of our ponds. Contract extraction revenue more than doubled in the current year as we continue to grow this service to third-party producers of astaxanthin biomass.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absorption, CAA, combination, comparison, constant, COVID, exclusion, extinguishment, freight, gain, idle, judgement, kilo, notice, overturn, permanent, Rev, Rul, spoilage, store, tourism, TRA

From filing 10-Q 2021 Q3